Apolipoprotein L1 gene variants in deceased organ donors are associated with renal allograft failure

American Journal of Transplantation

Volumn 15, Issue 6, 2015, Pages 1615-1622

  Freedman, B I ^a   Julian, B A ^b   Pastan, S O ^c   Israni, A K ^d,e   Schladt, D ^e   Gautreaux, M D ^a   Hauptfeld, V ^f   Bray, R A ^c   Gebel, H M ^c   Kirk, A D ^g   Gaston, R S ^b   Rogers, J ^a   Farney, A C ^a   Orlando, G ^a   Stratta, R J ^a   Mohan, S ^h   Ma, L ^a   Langefeld, C D ^a   Hicks, P J ^a   Palmer, N D ^a   Adams, P L ^a   Palanisamy, A ^a   Reeves Daniel, A M ^a   Divers, J ^a   more..

^a WAKE FOREST SCHOOL OF MEDICINE   (United States)

^b University of Alabama at Birmingham   (United States)

^c EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

^e MINNEAPOLIS MEDICAL RESEARCH FOUNDATION   (United States)

^f UNIVERSITY OF ALABAMA SCHOOL OF MEDICINE   (United States)

^g DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^h College of Physic and Surg ^*  (United States)

Author keywords

clinical research practice; donors and donation: deceased; genetics; genomics; kidney disease; kidney transplantation nephrology; molecular biology; translational research science

Indexed keywords

APOLIPOPROTEIN; APOLIPOPROTEIN L1; CALCINEURIN INHIBITOR; CORTICOSTEROID; PANEL REACTIVE ANTIBODY; UNCLASSIFIED DRUG; APOL1 PROTEIN, HUMAN; HIGH DENSITY LIPOPROTEIN;

ACUTE GRAFT REJECTION; AFRICAN AMERICAN; ARTICLE; COLD ISCHEMIA; DELAYED GRAFT FUNCTION; DNA DETERMINATION; ETHNICITY; FEMALE; GENETIC VARIABILITY; GENOTYPE; GRAFT FAILURE; GRAFT SURVIVAL; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY ALLOGRAFT; KIDNEY DONOR; KIDNEY GRAFT REJECTION; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; SINGLE NUCLEOTIDE POLYMORPHISM; UNITED STATES; ADOLESCENT; ADULT; ALABAMA; ALLOGRAFT; CLINICAL TRIAL; COMPARATIVE STUDY; DONOR; ETHNOLOGY; GENETIC VARIATION; GENETICS; GRAFT REJECTION; KIDNEY DISEASE; KIDNEY TRANSPLANTATION; MIDDLE AGED; MORTALITY; MULTICENTER STUDY; NORTH CAROLINA; RISK FACTOR; SURVIVAL RATE; TREATMENT OUTCOME; YOUNG ADULT;

ADOLESCENT; ADULT; ALABAMA; ALLOGRAFTS; APOLIPOPROTEIN L1; APOLIPOPROTEINS; BLACK OR AFRICAN AMERICAN; FEMALE; GENETIC VARIATION; GENOTYPE; GRAFT REJECTION; HUMANS; KIDNEY DISEASES; KIDNEY TRANSPLANTATION; LIPOPROTEINS, HDL; MALE; MIDDLE AGED; NORTH CAROLINA; RISK FACTORS; SURVIVAL RATE; TISSUE DONORS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84926493634     PISSN: 16006135     EISSN: 16006143     Source Type: Journal    
DOI: 10.1111/ajt.13223     Document Type: Article

References (42)

1. Department of Health and Human Services HRaSAHSBDoT. Organ procurement and transplantation network (OPTN) and scientific registry of transplant recipients (SRTR). OPTN/SRTR 2010 Annual Data Report. Rockville, MD, 2011.
2. Tanriover B, Mohan S, Cohen DJ, et al., Kidneys at higher risk of discard: Expanding the role of dual kidney transplantation. Am J Transplant 2014; 14: 404-415.
3. Takemoto S, Terasaki PI, Cecka JM, Cho YW, Gjertson DW,. Survival of nationally shared, HLA-matched kidney transplants from cadaveric donors. The UNOS Scientific Renal Transplant Registry. N Engl J Med 1992; 327: 834-839.
4. Drawz PE, Sedor JR,. Translating associations between common kidney diseases and genetic variation into the clinic. Semin Nephrol 2010; 30: 195-202.
5. Genovese G, Friedman DJ, Ross MD, et al., Association of trypanolytic ApoL1 variants with kidney disease in African Americans. Science 2010; 329: 841-845.
6. Tzur S, Rosset S, Shemer R, et al., Missense mutations in the APOL1 gene are highly associated with end stage kidney disease risk previously attributed to the MYH9 gene. Hum Genet 2010; 128: 345-350.
7. Kopp JB, Nelson GW, Sampath K, et al., APOL1 genetic variants in focal segmental glomerulosclerosis and HIV-associated nephropathy. J Am Soc Nephrol 2011; 22: 2129-2137.
8. Ashley-Koch AE, Okocha EC, Garrett ME, et al., MYH9 and APOL1 are both associated with sickle cell disease nephropathy. Br J Haematol 2011; 155: 386-394.
9. Lipkowitz MS, Freedman BI, Langefeld CD, et al., Apolipoprotein L1 gene variants associate with hypertension-attributed nephropathy and the rate of kidney function decline in African Americans. Kidney Int 2013; 83: 114-120.
10. Freedman BI, Langefeld CD, Andringa KK, et al., End-stage renal disease in African Americans with lupus nephritis is associated with APOL1. Arthritis Rheumatol 2014; 66: 390-396.
11. Parsa A, Kao WH, Xie D, et al., APOL1 risk variants, race, and progression of chronic kidney disease. N Engl J Med 2013; 369: 2183-2196.
12. Larsen CP, Beggs ML, Saeed M, Walker PD,. Apolipoprotein L1 risk variants associate with systemic lupus erythematosus-associated collapsing glomerulopathy. J Am Soc Nephrol 2013; 24: 722-725.
13. Vanhollebeke B, Pays E,. The trypanolytic factor of human serum: many ways to enter the parasite, a single way to kill. Mol Microbiol 2010; 76: 806-814.
14. Freedman BI, Kopp JB, Langefeld CD, et al., The apolipoprotein L1 (APOL1) gene and nondiabetic nephropathy in African Americans. J Am Soc Nephrol 2010; 21: 1422-1426.
15. Genovese G, Friedman DJ, Pollak MR,. APOL1 variants and kidney disease in people of recent African ancestry. Nat Rev Nephrol 2013; 9: 240-244.
16. Reeves-Daniel AM, Depalma JA, Bleyer AJ, et al., The APOL1 gene and allograft survival after kidney transplantation. Am J Transplant 2011; 11: 1025-1030.
17. Meier-Kriesche HU, Port FK, Ojo AO, et al., Effect of waiting time on renal transplant outcome. Kidney Int 2000; 58: 1311-1317.
18. Swanson SJ, Hypolite IO, Agodoa LY, et al., Effect of donor factors on early graft survival in adult cadaveric renal transplantation. Am J Transplant 2002; 2: 68-75.
19. Chakkera HA, O'Hare AM, Johansen KL, et al., Influence of race on kidney transplant outcomes within and outside the Department of Veterans Affairs. J Am Soc Nephrol 2005; 16: 269-277.
20. Callender CO, Cherikh WS, Traverso P, Hernandez A, Oyetunji T, Chang D,. Effect of donor ethnicity on kidney survival in different recipient pairs: an analysis of the OPTN/UNOS database. Transplant Proc 2009; 41: 4125-4130.
21. Lee BT, Kumar V, Williams TA, et al., The APOL1 genotype of African American kidney transplant recipients does not impact 5-year allograft survival. Am J Transplant 2012; 12: 1924-1928.
22. Leppke S, Leighton T, Zaun D, et al., Scientific registry of transplant recipients: Collecting, analyzing, and reporting data on transplantation in the United States. Transplant Rev (Orlando) 2013; 27: 50-56.
23. Cox DR,. Regression models and life-tables. J Royal Stat Soc, Series B 1972; 34: 187-220.
24. Therneau TM, Grambsch PM,. Modeling survival data: Extending the Cox model. New York, NY: Springer; 2000: p. 170-174.
25. Zeger SL, Liang KY,. Longitudinal data analysis for discrete and continuous outcomes. Biometrics 1986; 42: 121-130.
26. Lin DY, Wei LJ,. The robust inference for the Cox Proportional Hazards Model. J Am Stat Assoc 1989; 84: 1074-1078.
27. Fine J, Gray A,. A proportional Hazards Model for the Subdistribution of a competing risk. J Am Stat Assoc 1999; 94: 496-509.
28. Zhou B, Latouche A,. Competing risks regression for stratified and clustered data. R package version 1.1; 2013. http://CRAN R-project org/package = crrSC 2013.
29. Divers J, Nunez M, High KP, et al., JC polyoma virus interacts with APOL1 in African Americans with nondiabetic nephropathy. Kidney Int 2013; 84: 1207-1213.
30. Kopp JB,. JC viruria and kidney disease in APOL1 risk genotype individuals: Is this a clue to a gene x environment interaction? Kidney Int 2013; 84: 1069-1072.
31. Divers J, Palmer ND, Lu L, et al., Gene-gene interactions in APOL1-associated nephropathy. Nephrol Dial Transplant 2014; 29: 587-594.
32. Cohen DM, Mittalhenkle A, Scott DL, Young CJ, Norman DJ,. African American living-kidney donors should be screened for APOL1 risk alleles. Transplantation 2011; 92: 722-725.
33. Kofman T, Audard V, Narjoz C, et al., APOL1 polymorphisms and development of CKD in an identical twin donor and recipient pair. Am J Kidney Dis 2014; 63: 816-819.
34. Gibney EM, King AL, Maluf DG, Garg AX, Parikh CR,. Living kidney donors requiring transplantation: focus on African Americans. Transplantation 2007; 84: 647-649.
35. Lentine KL, Schnitzler MA, Xiao H, et al., Racial variation in medical outcomes among living kidney donors. N Engl J Med 2010; 363: 724-732.
36. Lentine KL, Schnitzler MA, Xiao H, et al., Consistency of racial variation in medical outcomes among publicly and privately insured living kidney donors. Transplantation 2014; 97: 316-324.
37. Gaston RS, Young CJ,. Living donor nephrectomy: understanding long-term risk in minority populations. Am J Transplant 2010; 10: 2574-2576.
38. Steiner RW,. "Normal for now" or "at future risk": A double standard for selecting young and older living kidney donors. Am J Transplant 2010; 10: 737-741.
39. Roberts JP, Wolfe RA, Bragg-Gresham JL, et al., Effect of changing the priority for HLA matching on the rates and outcomes of kidney transplantation in minority groups. N Engl J Med 2004; 350: 545-551.
40. Cannon RM, Brock GN, Marvin MR, Slakey DP, Buell JF,. The contribution of donor quality to differential graft survival in African American and Caucasian renal transplant recipients. Am J Transplant 2012; 12: 1776-1783.
41. Kasiske BL, Stewart DE, Bista BR, et al., The role of procurement biopsies in acceptance decisions for kidneys retrieved for transplant. Clin J Am Soc Nephrol 2014; 9: 562-571.
42. Israni AK, Salkowski N, Gustafson S, et al., New national allocation policy for deceased donor kidneys in the United States and possible effect on patient outcomes. J Am Soc Nephrol 2014; 25: 1842-1848.